Literature DB >> 1913697

The treatment of orthostatic hypotension with dihydroxyphenylserine.

R Freeman1, L Landsberg.   

Abstract

Neurogenic orthostatic hypotension is an incapacitating symptom of central and peripheral autonomic nervous system degeneration. It occurs in such clinical conditions as multiple system atrophy, pure autonomic failure, and small-fiber peripheral neuropathies. Although many treatments are available, their effects are inconsistent, unsustained, and complicated by side effects. 3,4-Dihydroxyphenylserine is a synthetic, unnatural amino acid that is an immediate norepinephrine precursor. There is theoretical and clinical evidence supporting the use of this agent in the treatment of neurogenic orthostatic hypotension in patients with peripheral and central autonomic nervous system dysfunction. We review the biochemistry, pharmacokinetics, and possible mechanisms of action and clinical utility of this agent in the treatment of neurogenic orthostatic hypotension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913697     DOI: 10.1097/00002826-199108000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  [33-year-old male patient with recurrent syncopes and orthostatic hypotension].

Authors:  H-G Justl; E G Hahn; C Maihöfner; I A Harsch
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

Review 2.  Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 3.  Dopamine beta-hydroxylase deficiency.

Authors:  Jean-Michel Senard; Philippe Rouet
Journal:  Orphanet J Rare Dis       Date:  2006-03-30       Impact factor: 4.123

Review 4.  Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Authors:  Stuart H Isaacson; Julia Skettini
Journal:  Vasc Health Risk Manag       Date:  2014-04-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.